Doxycycline Hyclate Solicitation
ID: SPE2D2-25-R-0004Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/757d97b4f2f54f1a8e44935f69963f16/view
Timeline
    Description

    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.

    Point(s) of Contact
    Courtney Hunter-Stangler
    (215) 737-6845
    Courtney.Hunter-Stangler@dla.mil
    Jason C. Wray
    (215) 737-0614
    Jason.Wray@dla.mil
    Files
    Title
    Posted
    Doxycycline Hyclate Solicitation - SPE2D2-25-R-0004.pdf
    The document is a government solicitation (No. SPE2D2-25-R-0004) for the procurement of pharmaceutical products, specifically Doxycycline Hyclate tablets in various quantities and packaging configurations. It outlines essential information for potential contractors, including submission guidelines, contract clauses, and evaluation criteria. The proposal requires offers to be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), with a closing date of January 21, 2025. It specifies requirements for large business offerors to submit a subcontracting plan consistent with public law. Additionally, contractors are evaluated based on compliance with federal regulations pertaining to business ethics, subcontracting plans, and the acquisition of defense telecommunications equipment. The statement of work delineates objectives related to supply compliance, delivery expectations, product registration, and quality control measures, while the contract clauses reflect the provisions of the Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS). The document emphasizes the importance of adherence to legal and ethical guidelines to ensure fair procurement processes and quality service delivery in federal contracting. This solicitation serves as a formal request for proposals, reflecting compliance with federal acquisition policies to ensure effective procurement in support of governmental functions.
    Doxycycline Hyclate Solicitation - SPE2D2-25-R-0004 Amendment 0001.pdf
    The federal solicitation SPE2D2-25-R-0004 outlines a request for proposals regarding the supply of Doxycycline Hyclate tablets in various quantities. The document specifies submission requirements through the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and emphasizes that submissions via email or postal mail are not authorized. A detailed Statement of Work includes background, objectives, contract terms, special considerations, pricing, delivery, and transition protocols. Furthermore, the solicitation incorporates key contract clauses that contractors must comply with, including requirements about business ethics, subcontracting plans, and performance assessments. Additional caution notices highlight the importance of compliance with federal regulations regarding telecommunications equipment, trade agreements, and duty-free entries. The solicitation aims to expedite procurement while maintaining regulatory standards, ensuring contractors understand their obligations and the importance of ethical practices in government contracting.
    SF30_SPE2D225R00040001.PDF
    The document is an amendment to a federal solicitation concerning contract SPE2D225R0004. The primary purpose is to modify the information regarding the supply schedule for Clinical Item (CLIN) 0009, which was incorrectly listed as 100 count bottles. The amendment officially acknowledges the changes without altering the overall terms and conditions of the original contract. It requires contractors to acknowledge receipt of this amendment to avoid the rejection of their proposals and specifies the contractor's obligation to return the signed document. The file also indicates the issuing agent is the DLA Troop Support Medical Supply Chain in Philadelphia, PA. This amendment reflects typical government contractual procedures aimed at ensuring accuracy in the procurement process, emphasizing the importance of maintaining current and correct supply specifications.
    Lifecycle
    Title
    Type
    Doxycycline Hyclate Solicitation
    Currently viewing
    Solicitation
    Doxycycline Hyclate
    Presolicitation
    Similar Opportunities
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotes for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective and integrated pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs, including neurological agents, antibiotics, oncological agents, and various other pharmaceutical categories. Interested manufacturers must submit their quotes by January 16, 2025, with a pre-quotation teleconference scheduled for January 8, 2025, to discuss the requirements and expectations. For further inquiries, manufacturers can contact Tracy Banks at tracy.e.banks2.civ@health.mil or Patricia Tyson at patricia.a.tyson3.ctr@health.mil.
    65--DANTROLENE SODIUM F
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking quotes for the procurement of Dantrolene Sodium F, a critical medical supply. The solicitation includes multiple line items, each requiring a quantity of three units to be delivered to the W05J Medical Maintenance Operations Division at Tobyhanna, with a delivery timeline of five days after order. Dantrolene Sodium is essential for treating malignant hyperthermia and is vital for patient safety in medical settings. Interested vendors must submit their quotes electronically, and any inquiries regarding the solicitation should be directed to the buyer via email at DibbsBSM@dla.mil.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.